<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic kidney disease and coronary heart disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic kidney disease and coronary heart disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic kidney disease and coronary heart disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Sarnak, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Michael Gibson, MS, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William L Henrich, MD, MACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary C Curhan, MD, ScD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic kidney disease (CKD) is an independent risk factor for the development of coronary artery disease, and for more severe coronary heart disease (CHD) [<a href="#rid1">1-5</a>]. CKD is also associated with adverse outcomes in those with existing cardiovascular disease [<a href="#rid6">6-8</a>]. This includes increased mortality after an acute coronary syndrome, after percutaneous coronary intervention (PCI) with or without stenting [<a href="#rid9">9-16</a>], and after coronary artery bypass. In addition, patients with CKD are more likely to present with atypical symptoms, which may delay diagnosis and adversely affect outcomes [<a href="#rid17">17,18</a>].</p><p>An overview of CKD and CHD is presented in this topic review. Issues related to CHD in patients with end-stage kidney disease (ESKD) and general discussions of risk factors for cardiovascular disease and interventions for secondary prevention are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1892.html" rel="external">"Clinical manifestations and diagnosis of coronary artery disease in end-stage kidney disease (dialysis)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1960.html" rel="external">"Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">CHRONIC KIDNEY DISEASE AS AN INDEPENDENT RISK FACTOR FOR CHD</span><span class="headingEndMark"> — </span>Both decreased glomerular filtration rate (GFR) and increased proteinuria increase the risk of cardiovascular disease. These associations have been shown in both community-based populations (ie, cohorts that were not selected specifically to enroll individuals with CKD or cardiovascular disease), and in populations of patients at high cardiovascular risk (ie, cohorts in which patients with preexisting cardiovascular disease or cardiovascular disease risk factors were specifically recruited).</p><p class="headingAnchor" id="H4"><span class="h2">Association between CKD and CHD in community-based populations</span><span class="headingEndMark"> — </span>Numerous observational studies have shown that a reduced GFR and proteinuria are both independently associated with an increased risk of cardiovascular events in community-based populations of patients who were not selected based upon the presence of known kidney or cardiovascular disease [<a href="#rid1">1,6,19-55</a>]. In addition, the association between CKD and cardiovascular events may be stronger among Black individuals as compared with White individuals [<a href="#rid33">33,37,54</a>].</p><p>The best data come from a meta-analysis of general population cohorts that included 105,872 participants with urine albumin-to-creatinine ratio (ACR) measurements and 1,128,310 participants with urine protein dipstick measurements; all had documented baseline estimated GFR [<a href="#rid22">22</a>]. Compared with participants whose estimated GFR was 95 mL/min/1.73 m<sup>2</sup>, hazard ratios (HR) for all-cause mortality during 7.9 years of follow-up were 1.18 (95% CI 1.05-1.32), 1.57 (95% CI 1.39-1.78), and 3.14 (95% CI 2.39-4.13) for estimated GFRs of 60, 45, and 15 mL/min per 1.73 m<sup>2</sup>, respectively. Similar outcomes were observed for cardiovascular mortality, and similar results were obtained in older and younger individuals (age greater than 65 years versus 65 years or less). A higher risk for all-cause mortality was observed at estimated GFRs greater than 105 mL/min per 1.73 m<sup>2</sup>; however, this association may reflect either reduced muscle mass from ill health leading to a lower creatinine value, or a high prevalence of individuals with diabetes or obesity causing hyperfiltration and a low creatinine [<a href="#rid56">56</a>].</p><p>Proteinuria was independently associated with increased all-cause and cardiovascular mortality in this study [<a href="#rid22">22</a>]. Compared with an albumin-to-creatinine ratio (ACR) of 0.6 mg/mmol (6 mg/g), the adjusted hazard ratio for all-cause mortality was 1.20 (95% CI 1.15-1.26); 1.63 (95% CI 1.50-1.77); and 2.20 (95% CI 1.97-2.51) for ACRs of 1.1 (10 mg/g); 3.4 (30 mg/g); and 33.9 mg/mmol (300 mg/g), respectively. Similar findings were observed for cardiovascular mortality. An ACR greater than 3.4 mg/mmol (30 mg/g) was associated with a greater than twofold mortality risk for all levels of estimated GFR except the lowest (&lt;30 mL/min per 1.73 m<sup>2</sup>). Among participants with dipstick determination of proteinuria, a trace urine positive dipstick was also associated with increased all-cause and cardiovascular mortality for all levels of kidney function, although large heterogeneity was present between studies that provided only dipstick measurement of protein.</p><p>Given that CKD alone appears to increase the risk of CHD in the general population, it is not surprising that the Framingham risk score, the traditional method to analyze future cardiovascular risk among individuals without CKD, provides poor overall accuracy in predicting cardiovascular events in patients with CKD [<a href="#rid57">57,58</a>], while inclusion of estimated GFR and ACR with traditional cardiovascular risk factors improves the ability to forecast events [<a href="#rid59">59</a>]. This may be partly due to the markedly increased cardiac event rate and overall death rate among such patients. Attempts have been made to improve the predictive accuracy of the Framingham risk equations by including kidney parameters. Such efforts have been successful in some but not all populations [<a href="#rid57">57,60,61</a>], suggesting that new prediction equations must be developed to help predict future events among patients with CKD.</p><p>Despite the preponderance of evidence in favor of an increase in risk with CKD alone, a few studies have found that less severe kidney disease is not an independent risk factor for adverse cardiovascular outcomes [<a href="#rid62">62,63</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Association between CKD and CHD among those at high cardiovascular risk</span><span class="headingEndMark"> — </span>Numerous secondary analyses of studies that enrolled patients with known risk factors for cardiovascular disease (such as hypertension and diabetes), or preexisting cardiovascular disease, have shown that the presence or development of various degrees of kidney dysfunction is independently associated with cardiovascular events [<a href="#rid20">20,52,53,59,64-74</a>]. In addition, accounting for estimated GFR and ACR in conjunction with traditional risk factors improves the ability to predict cardiovascular events in patients at high cardiovascular risk [<a href="#rid59">59</a>].</p><p>The magnitude of the association of kidney function, albuminuria, and outcomes was illustrated in a collaborative meta-analysis of 10 cohorts with 266,975 patients who had hypertension, diabetes, cardiovascular disease, or a combination of these disorders [<a href="#rid64">64</a>]. Compared with a reference estimated GFR of 95 mL/min per 1.73 m<sup>2</sup>, the hazard ratios for cardiovascular mortality were 1.11 for an estimated GFR of 60 mL/min per 1.73 m<sup>2</sup>, 1.73 for an estimated GFR of 45 mL/min per 1.73 m<sup>2</sup>, and 3.08 for an estimated GFR of 15 mL/min per 1.73 m<sup>2</sup>. Similar findings were noted for all-cause mortality, and the associations were similar in younger and older patients. A monotonic association between higher ACR and risk of both cardiovascular and all-cause mortality was also noted.</p><p class="headingAnchor" id="H6"><span class="h2">CKD as a CHD risk equivalent</span><span class="headingEndMark"> — </span>The above evidence that mild to moderate CKD is associated with an adverse cardiovascular prognosis led both the National Kidney Foundation and the American College of Cardiology/American Heart Association to recommend in older guidelines that CKD be considered a CHD risk equivalent [<a href="#rid1">1,75-78</a>]. Consistent with this, the number of cardiovascular events attributable to CKD in the Alberta Kidney Disease Network and Atherosclerosis Risk In Communities (ARIC) studies were comparable to the number of events attributable to diabetes, another factor considered to be a CHD risk equivalent [<a href="#rid37">37,79</a>].</p><p>In addition, the nine-year rates of cardiovascular death among 1899 individuals in the Cardiovascular Health Study (CHS) were as follows (CKD was defined as an estimated GFR less than 60 mL/min per 1.73 m<sup>2</sup>) [<a href="#rid80">80</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>History of myocardial infarction, but no diabetes or CKD: 15.7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>History of diabetes, but no myocardial infarction or CKD: 15.8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>History of CKD, but no myocardial infarction or diabetes: 13 percent</p><p></p><p>Although CKD was a powerful risk factor for cardiovascular disease in these and other studies, the generalization that CKD is a CHD risk equivalent for all persons with CKD may not be warranted for several reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Some studies contradict the concept that CKD is a CHD risk equivalent. In the Alberta Kidney Disease Network cohort, for example, the four-year incidence of myocardial infarction was nearly threefold higher among those who had a prior history of myocardial infarction (7.7 percent) compared with those without a prior history of myocardial infarction but who had CKD (2.8 percent) [<a href="#rid79">79</a>]. The incidence of myocardial infarction among those who had a prior history of myocardial infarction but no diabetes and no CKD was more than twice the incidence among those with CKD but not prior myocardial infarction. Similarly, a secondary analysis from the ARIC study suggested that the risk associated with CKD was not comparable to the risk associated with a prior myocardial infarction [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of heart disease in those with CKD appears to vary based upon absolute level of kidney function and degree of proteinuria, as well as the rate at which these factors change. The simultaneous presence of both decreased kidney function and increased proteinuria further enhance the risk for cardiovascular disease compared with the risk associated with either problem alone [<a href="#rid21">21-23,64,79</a>]. In addition, the rate of decline of kidney function and the rate of increase of proteinuria also correlate with varying risks of adverse cardiovascular events [<a href="#rid82">82-84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Even patients with the same degree of kidney dysfunction may <strong>not</strong> have the same risk of cardiovascular disease since the risk of cardiovascular disease in a patient with CKD is in part related to the presence and extent of significant comorbidities. As an example, the overall risk for a 25-year-old nonsmoking man with moderate CKD due to IgA nephropathy is not the same as that of a 65-year-old man with a similar degree of CKD but with a long history of smoking, hypertension, and elevated serum cholesterol levels. Thus, the proper assessment of overall cardiovascular risk in patients with CKD requires an adequate assessment for the presence and severity of the other major risk factors for cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p></p><p>The concept of CHD risk equivalency was developed by expert panels as a means to help clinicians make decisions about how aggressively to treat their patients to prevent CHD [<a href="#rid85">85</a>]. As an example, while it is fairly simple to identify a patient who has diabetes or CKD, and thus institute aggressive therapy for secondary prevention of CHD, it is more cumbersome to calculate every patient's 10-year cardiovascular risk. Approximately half of adults in the United States with CKD have another CHD risk equivalent, specifically a prior history of myocardial infarction or stroke, diabetes, angina, or a calculated Framingham 10-year CHD risk greater than 20 percent [<a href="#rid86">86</a>]. Thus, the question of whether CKD is a CHD risk equivalent is germane to whether millions of additional patients with CKD should receive aggressive therapy to lower their LDL cholesterol and blood pressure, and whether they should receive antiplatelet therapy. In general, many expert panels are moving away from the concept of "risk equivalency" and are, instead, basing their recommendations for preventative therapies upon the predicted 10-year CHD risk. These issues are discussed in detail below. (See <a class="local">'Reduction of CHD risk in patients with CKD'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">Limitations of the data</span><span class="headingEndMark"> — </span>One possible limitation in nearly all of the above reports is that kidney function was indirectly estimated. Since the various estimates provide results that may differ from each other, the association between kidney function and cardiovascular risk is affected by the method selected to estimate kidney function. The association may be further compromised because some of the formulas utilized are based directly upon variables linked with cardiovascular risk, such as age, weight, and body mass index.</p><p>This difficulty was shown using data from 8592 participants in the PREVEND study, in which the association between various cardiovascular risk factors and kidney function was examined [<a href="#rid87">87,88</a>]. Kidney function was estimated using creatinine clearance (based upon two 24-hour urine collections), and the Cockcroft-Gault and Modification of Diet in Renal Disease (MDRD) formulas [<a href="#rid87">87</a>]; the various cardiovascular risk factors examined included blood pressure, serum cholesterol and glucose levels, age, sex, weight, waist-to-hip ratio, and body mass index. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p>Markedly different relationships emerged when each method for estimating kidney function was plotted against each cardiovascular risk factor. These varied relationships were most pronounced for age, weight, and body mass index, and less pronounced (but still statistically significant) for blood pressure, and serum cholesterol and glucose levels. As a result, caution must be exercised when studying the relationships among cardiovascular risk factors, indirect estimates of kidney function, and cardiovascular risk.</p><p class="headingAnchor" id="H786389950"><span class="h3">Cystatin C and other markers of kidney function</span><span class="headingEndMark"> — </span>Another potential limitation of kidney function estimates in the vast majority of studies mentioned above is that level of GFR may not be accurately assessed using creatinine-based equations, particularly in those with estimated GFR values greater than 60 mL/min/1.73 m<sup>2</sup>. In these individuals, cystatin C and other markers of kidney function (such as beta-trace protein and beta-2-microglobulin) may be more sensitive measures of decreased GFR, and also more strongly associated with fatal and nonfatal cardiovascular events, than creatinine and creatinine-based estimates of GFR [<a href="#rid43">43-50,89,90</a>]. As an example, the risk of death relative to the cystatin C concentration increased in a dose-response fashion in one study [<a href="#rid43">43</a>]. Relative to the first quintile, the adjusted hazard ratio of cardiovascular death for the third, fourth, and fifth quintiles (the fifth quintile further subdivided into thirds) of cystatin C levels were 1.93, 1.99, and 2.48 to 2.83, respectively. In contrast, a significant association with adverse outcomes was only observed among those in the lowest quintile of GFR estimated from the plasma creatinine concentration. In addition, compared with creatinine-based estimation of GFR, estimation using a cystatin C-based equation improves risk stratification for mortality, cardiovascular events, and end-stage kidney disease (ESKD) [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p>These results suggest that elevated plasma cystatin C concentration may be a more accurate measure of cardiovascular risk than elevated plasma creatinine concentration. However, some have postulated that non-renal determinants of cystatin C levels, such as increased inflammation and other cardiovascular factors, may underlie this association. In addition, cystatin C is not as yet routinely measured.</p><p class="headingAnchor" id="H599735133"><span class="h1">PRESENCE OF TRADITIONAL AND NONTRADITIONAL CARDIOVASCULAR RISK FACTORS IN CKD</span><span class="headingEndMark"> — </span>Patients with CKD often have numerous traditional and nontraditional risk factors for the development of cardiovascular disease. Traditional risk factors appear to be associated with much larger absolute increases in risk in comparison with nontraditional risk factors in the earlier stages of CKD [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H599735140"><span class="h2">Traditional risk factors</span><span class="headingEndMark"> — </span>Traditional cardiovascular risk factors, such as hypertension (which may be accompanied by left ventricular hypertrophy), smoking, diabetes, dyslipidemia and older age, are highly prevalent in CKD populations [<a href="#rid1">1,92,93</a>]. The number of cardiovascular risk factors appears to correlate with the severity of kidney dysfunction [<a href="#rid93">93</a>]. These are discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3872.html" rel="external">"Overview of hypertension in acute and chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p>Patients with CKD are also more likely to have the metabolic syndrome, which could contribute to the increase in cardiovascular risk [<a href="#rid3">3,94</a>]. This syndrome is defined as some combination of insulin resistance, dyslipidemia, elevated serum glucose, abdominal obesity, and hypertension. (See  <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>.)</p><p class="headingAnchor" id="H599735147"><span class="h2">Nontraditional risk factors</span><span class="headingEndMark"> — </span>Possible risk factors that are relatively unique to patients with moderate to severe CKD include retention of uremic toxins, anemia, elevated levels of certain cytokines, positive calcium balance, abnormalities in bone mineral metabolism, and/or an "increased inflammatory-poor nutrition" state [<a href="#rid4">4,95</a>]. How these risk factors may lead to cardiovascular disease is unclear. As an example, disorders of bone mineral metabolism in patients with CKD have often been linked to coronary artery calcification. However, while there is a consistent association between CKD and a higher burden of coronary artery calcification [<a href="#rid96">96-98</a>], the associations among phosphorus, calcium, and parathyroid hormone with coronary artery calcification in these patients is inconsistent [<a href="#rid99">99-101</a>]. (See  <a class="medical medical_review" href="/z/d/html/1960.html" rel="external">"Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)"</a> and  <a class="medical medical_review" href="/z/d/html/1939.html" rel="external">"Inflammation in patients with kidney function impairment"</a> and  <a class="medical medical_review" href="/z/d/html/5297.html" rel="external">"Coronary artery calcium scoring (CAC): Overview and clinical utilization"</a>.)</p><p>Elevated levels of C-reactive protein (CRP) and asymmetric dimethylarginine, both of which are typically found in patients with CKD, were both independently associated with an increased risk of all-cause and cardiovascular mortality in the Modification of Diet in Renal Disease (MRDR) study [<a href="#rid102">102,103</a>], although a similar relation between CRP and cardiovascular disease was not observed in the <a class="drug drug_general" data-topicid="8640" href="/z/d/drug information/8640.html" rel="external">Irbesartan</a> for Diabetic Nephropathy trial [<a href="#rid104">104</a>]. Hyperhomocysteinemia has also been inconsistently associated with increased cardiovascular risk [<a href="#rid105">105-107</a>].</p><p>There is also a relationship between cardiovascular disease and moderately increased albuminuria (formerly called "microalbuminuria") among nondiabetic patients with normal estimated GFR. However, some disagree with the KDOQI and KDIGO working groups that isolated moderately increased albuminuria (ie, without a reduction in GFR or some other kidney abnormality) necessarily reflects kidney disease among nondiabetic patients [<a href="#rid75">75</a>]. It correlates best with generalized endothelial dysfunction and is associated with an increase in cardiovascular risk. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Definition and classification'</a> and  <a class="medical medical_review" href="/z/d/html/1545.html" rel="external">"Moderately increased albuminuria (microalbuminuria) and cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H599734827"><span class="h1">COMPETING RISKS OF CARDIOVASCULAR AND END-STAGE KIDNEY DISEASE</span><span class="headingEndMark"> — </span>Morbidity and mortality from cardiovascular disease among those with CKD is high. The risk of death, particularly due to cardiovascular disease, is typically higher than the risk of eventually requiring kidney replacement therapy. However, this risk varies with age and other factors. In many studies, older patients with less severe CKD and lower levels of proteinuria are more likely to die (usually due to cardiovascular disease) before needing kidney replacement therapy, while younger patients with proteinuria and diseases localized to the kidney are more likely to ultimately need kidney replacement therapy [<a href="#rid20">20,55,71,108-112</a>]. This is illustrated by the following examples:</p><p class="bulletIndent1"><span class="glyph">●</span>The following three studies largely include older patients identified through Medicare participation or through the Veteran's Affairs Network:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a study of over 1,000,000 individuals enrolled in the Medicare program in the United States, outcomes were reported for several groups, including those with CKD but no diabetes (2.2 percent) and both CKD and diabetes (1.6 percent) [<a href="#rid20">20</a>]. After two years of follow-up, the rates for requiring kidney replacement therapy were 1.6 and 3.4 per 100 patient-years for patients with CKD alone and those with both disorders, respectively; by comparison, the death rates were 17.7 and 19.9 per 100 patient-years. In addition, rates for atherosclerotic vascular disease for these two groups were 35.7 and 49.1, while heart failure rates were 30.7 and 52.3, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A longitudinal follow-up of nearly 30,000 older patients with estimated glomerular filtration rates (GFR) of less than 90 mL/min per 1.73 m<sup>2</sup> reported the rate of kidney replacement and death at five years [<a href="#rid108">108</a>]. The rate of kidney replacement therapy in those with stage 2, 3, or 4 disease was 1.1, 1.3, and 19.9 percent, respectively; by comparison, the mortality rate was 19.5, 24.3, and 45.7 percent. A higher incidence of coronary artery disease, heart failure, diabetes mellitus, and anemia was noted in those who died.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a report of over 12,000 older patients with diabetes, 48 percent had CKD defined as GFR less than 60 mL/min per 1.73 m<sup>2</sup>, or proteinuria [<a href="#rid109">109</a>]. After three years of follow-up, mortality rates were 6, 10, 20 and 30 percent for patients with CKD stages 2, 3, 4 and 5, respectively, compared to 5 percent for those with preserved kidney function at baseline. Rates of progression to end-stage kidney disease (ESKD) were much lower, less than 1 percent for stages 2 and 3, and 14 percent for stage 4.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The nondiabetic patients in the MDRD study included a broad range of ages, causes of kidney disease, baseline GFR, and baseline protein excretion. After nearly 12 years of follow-up, 936 patients (56 percent) developed ESKD, and 369 (22 percent) died [<a href="#rid113">113</a>]. Death prior to ESKD was more likely to occur in older as compared with younger individuals. In those patients older than 65 years, for example, 42 percent developed ESKD and 22 percent died before developing ESKD. However, in those 45 years or younger, 65 percent developed ESKD and less than 1 percent died before developing ESKD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The following are two studies with long-term observations from two cohorts of younger individuals with type 1 diabetes and nephropathy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The rate of ESKD incidence was substantially greater than the mortality rate (35.5 versus 9.5 percent) in a cohort of 592 young (median age 42 years) patients with type 1 diabetes followed for 10 years [<a href="#rid110">110</a>]. All patients in this study had at least 300 mg/day of proteinuria, and 60 percent of patients had an estimated GFR less than 60 mL/min per 1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar results were observed in a cohort of 423 young (median age 39 years) patients with type 1 diabetes, at least 300 mg/day of proteinuria, and a median baseline estimated GFR of 66 mL/min per 1.73 m<sup>2</sup> [<a href="#rid111">111</a>]. During 15 years of follow-up, 41 percent of patients developed ESKD, while 7 percent died without developing ESKD.</p><p></p><p>Although these data suggest that age differences determine whether or not patients with CKD will develop ESKD before dying, this observation may be biased by study design. Patients enrolled into studies of cardiovascular disease tend to be older and have less severe kidney disease than patients enrolled into studies of kidney disease. In addition, older patients with severe kidney dysfunction are more likely to develop ESKD before dying, as was observed in 3228 older individuals with type 2 diabetes and nephropathy (mean age 59 years, estimated GFR 44 mL/min per 1.73 m<sup>2</sup>, and mean urine albumin-to-creatinine ratio 1.37 g/g) [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H11"><span class="h1">REDUCTION OF CHD RISK IN PATIENTS WITH CKD</span><span class="headingEndMark"> — </span>In patients without CKD, risk factor modification and beneficial lifestyle changes can substantially decrease morbidity and mortality in those with coronary, cerebrovascular, or peripheral artery disease. These modalities include therapy with statins, control of hypertension, cessation of smoking, maintaining ideal body weight and an active lifestyle, glycemic control in diabetes, and the use of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. A review of the data supporting these interventions is presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p>In the past, patients with CKD were largely excluded from clinical trials of patients with coronary artery disease. A 2006 survey of the published literature noted that 75 percent of coronary artery disease trials excluded patients with CKD and only 7 percent reported baseline kidney function [<a href="#rid115">115</a>]. Similar observations were reported in a contemporaneous survey [<a href="#rid116">116,117</a>]. However, randomized trials have subsequently been performed specifically in patients with CKD, particularly regarding statin therapy. (See <a class="local">'CKD as a CHD risk equivalent'</a> above.)</p><p>As noted above, we do <strong>not</strong> agree with the generalization that CKD is a CHD risk equivalent for all persons with CKD. Our approach is instead based upon the available data and an assessment of future cardiovascular risk. This evidence, which is presented below, supports the following approach to reduce the risk of atherosclerotic cardiovascular disease in most patients with CKD not requiring dialysis:</p><p class="bulletIndent1"><span class="glyph">●</span>Statin therapy. (See <a class="local">'Statin therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with albuminuric CKD (defined as albuminuria greater than 300 mg/day), we recommend angiotensin blockade as part of the antihypertensive regimen. Goal blood pressure in patients with CKD is presented elsewhere. (See <a class="local">'Blood pressure control'</a> below and  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy. (See <a class="local">'Antiplatelet therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In all patients, smoking cessation, maintenance of an ideal body weight, an active lifestyle, and, in patients with diabetes, glycemic control. (See <a class="local">'Other issues'</a> below.)</p><p></p><p>The KDIGO guidelines also consider persistent proteinuria, including moderately increased albuminuria (formerly called "microalbuminuria"), to be part of CKD and therefore associated with increased CHD risk even if estimated glomerular filtration rate (GFR) is normal. We do not agree with applying this paradigm to all patients. As an example, it is unknown whether a 25-year-old nonsmoker with IgA nephropathy, normal serum creatinine concentration, and normal blood pressure is at increased cardiovascular risk in the absence of progressive disease. Such patients should clearly be followed carefully and patient values should be taken into account when considered how aggressively one would modify coronary risk factors. Issues related to moderately increased albuminuria are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1545.html" rel="external">"Moderately increased albuminuria (microalbuminuria) and cardiovascular disease"</a>.)</p><p>Secondary prevention of cardiovascular disease in patients with end-stage kidney disease (ESKD) on maintenance dialysis or those with a kidney transplant are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1962.html" rel="external">"Secondary prevention of cardiovascular disease in end-stage kidney disease (dialysis)"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">"Hypertension after kidney transplantation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7303.html" rel="external">"Lipid abnormalities after kidney transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Statin therapy</span><span class="headingEndMark"> — </span>Most evidence for the use of statins in patients with mild to moderate CKD comes from post-hoc subgroup analyses of randomized trials that were not intended to include patients with decreased kidney function. (See  <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">"Lipid management in patients with nondialysis chronic kidney disease"</a>.) One randomized trial, the Study of Heart and Renal Protection (SHARP) trial, specifically evaluated cholesterol lowering with a statin to prevent major vascular events in patients with CKD.</p><p>The findings from the SHARP trial echoed the observations made in CKD subgroups from other randomized trials: treatment of patients with CKD not requiring dialysis with a statin leads to a significant reduction in cardiovascular events. Patients who received statin therapy in SHARP also received <a class="drug drug_general" data-topicid="8790" href="/z/d/drug information/8790.html" rel="external">ezetimibe</a>, although it is not clear if ezetimibe contributed to the clinical benefit. A detailed discussion of these findings and recommendations regarding statin use in CKD are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">"Lipid management in patients with nondialysis chronic kidney disease"</a>.)</p><p>However, these trials mainly enrolled older patients with various comorbid conditions such as smoking, diabetes, and hypertension. Whether statin therapy would be beneficial in younger patients who have CKD due to primary kidney disease (such as IgA nephropathy or autosomal dominant polycystic kidney disease) rather than a systemic disease (such as diabetes) is unclear. We would initiate statin therapy in most patients who have an estimated GFR less than 60 mL/min per 1.73 m<sup>2</sup>; detailed recommendations are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">"Lipid management in patients with nondialysis chronic kidney disease", section on 'Treatment'</a>.)</p><p>A related issue is whether statins provide cardiovascular protection due in part to their pleiotropic effects that are independent of lipid lowering in patients with and without CKD. (See  <a class="medical medical_review" href="/z/d/html/4546.html" rel="external">"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease"</a>.)</p><p>There are as yet no trials that have compared cardiovascular outcomes among patients with dyslipidemia who were randomly assigned to specific target lipid levels rather than specific statin doses. When the results of multiple trials are considered, each using a fixed <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> dose, the rate of major cardiovascular events falls linearly with the reduction in LDL cholesterol [<a href="#rid118">118</a>]. However, there is as yet no good evidence that titrating statin therapy to achieve specific target LDL levels in patients at increased cardiovascular risk is associated with improved cardiovascular outcomes. Hence, the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on management of dyslipidemia in CKD did not base their suggestions upon target levels of LDL cholesterol. Rather, they recommend standard doses based upon cardiovascular risk and level of estimated GFR. (See  <a class="medical medical_review" href="/z/d/html/7204.html" rel="external">"Lipid management in patients with nondialysis chronic kidney disease", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p>Although the evidence is weak, there are also data suggesting that lipid lowering with statins may be associated with a slower rate of loss of GFR in patients with mild to moderate CKD.</p><p class="headingAnchor" id="H13"><span class="h2">Blood pressure control</span><span class="headingEndMark"> — </span>Numerous trials of patients with primary hypertension (formerly called "essential" hypertension) have shown that blood pressure control improves cardiovascular outcomes. Goal blood pressure, including in patients with chronic kidney disease and those at high risk for cardiovascular events, is presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p>Post-hoc analyses of CKD subgroups from cardiovascular trials suggest that antihypertensive therapy reduces the risk of cardiovascular events [<a href="#rid65">65,72,119,120</a>]. However, no specific antihypertensive drug (eg, angiotensin-converting enzyme [ACE] inhibitors) provides preferential cardiovascular benefit, at least in patients with non-proteinuric CKD. As an example, a meta-analysis examined the cardiovascular outcomes and mortality of 30,295 patients with an estimated GFR &lt;60 mL/min/1.73 m<sup>2</sup> from 26 randomized hypertension trials; 93 percent of patients were non-proteinuric [<a href="#rid119">119</a>]. Follow-up of these patients for approximately four to five years yielded the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Compared with placebo, both ACE inhibitors (3.2 percent absolute decrease) and calcium channel antagonists (2.1 percent absolute decrease) reduced the incidence of cardiovascular events (stroke, myocardial infarction, heart failure) and mortality. Trials comparing diuretics or beta blockers with placebo were not included in the meta-analysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In drug versus drug trials, the incidence of cardiovascular events and mortality were similar comparing angiotensin inhibitors with either diuretics or beta blockers (18 versus 19 percent) or with calcium channel antagonists (23 versus 24 percent).</p><p></p><p>In contrast to patients with non-proteinuric CKD, there is some evidence of benefit from specific antihypertensive drugs (ie, ACE inhibitors) in patients with proteinuria (defined as more than 500 to 1000 mg/day). In such patients, ACE inhibitors and may reduce the progression of kidney disease. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Antiplatelet therapy</span><span class="headingEndMark"> — </span>Long-term <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy reduces the risk of subsequent myocardial infarction (MI), stroke, and vascular death among patients <strong>without</strong> CKD, but with a wide range of prior manifestations of cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>.)</p><p>There are fewer data related to the effectiveness and safety of antiplatelet therapy in patients <strong>with</strong> CKD [<a href="#rid121">121,122</a>]. The best data come from a meta-analysis of 27,139 patients with CKD who participated in 50 randomized trials that tested the efficacy of antiplatelet agents (mostly <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) for prevention of CVD [<a href="#rid121">121</a>]. Antiplatelet therapy significantly reduced the incidence of fatal or nonfatal myocardial infarction as compared with either placebo or no therapy (6.7 versus 7.0 percent, or 3 myocardial infarctions prevented for every 1000 patients treated). However, antiplatelet therapy also significantly increased the rate of major bleeding (4.4 versus 2.9 percent, or 15 additional major bleeding events for every 1000 patients treated). Antiplatelets had no effect on stroke or mortality. The results were similar in patients of all CKD stages.</p><p>Based upon these data, we suggest that decisions about antiplatelet therapy to prevent cardiovascular disease in patients with CKD be individualized depending upon the patient's overall risk for CHD (for example, a prior history of myocardial infarction) and for bleeding, and also upon their preferences. This suggestion is broadly consistent with guidelines made by the Kidney Disease Improving Global Outcomes (KDIGO) report on the management of CKD [<a href="#rid123">123</a>]. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>.)</p><p>In addition to cardiovascular disease, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy may reduce the risk of cancer incidence. This should also be considered in the decision about whether or not to use aspirin in patients with CKD. (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer"</a>.)</p><p>The prescription of low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is probably safe in most patients with CKD. The KDOQI clinical practice guidelines for controlling the epidemic of CV disease in CKD, as well as other KDOQI guidelines, can be accessed through the National Kidney Foundation's web site at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.kidney.org%2Fprofessionals%2Fguidelines&amp;token=mwx%2FWFqfIsxpjED21OsijeC6nVb9OOdf2ctFKSDhUkeo7woDHDqqTAFuB14mPyNw1FjMB29uSsN6BBA179a0fw%3D%3D&amp;TOPIC_ID=7190" target="_blank">www.kidney.org/professionals/kdoqi/guidelines.cfm</a>.</p><p class="headingAnchor" id="H15"><span class="h2">Other issues</span><span class="headingEndMark"> — </span>In general, similar considerations apply to patients with and without kidney dysfunction concerning interventions for cessation of smoking, maintaining ideal body weight and an active lifestyle, and glycemic control in diabetes. Recommendations concerning these issues are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p>Measures aimed at correcting other nontraditional cardiovascular risk factors in those with CKD, such as anemia, calcium-phosphate disorders, systemic inflammation, and increased oxidative stress, may also improve cardiovascular outcomes. This is also discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1935.html" rel="external">"Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">TREATMENT OF CORONARY HEART DISEASE</span><span class="headingEndMark"> — </span>Patients with CKD require drug dose adjustments and have a higher risk of drug-related adverse effects. Despite the increased risk of adverse effects, the treatments used for established CHD and acute coronary syndrome that are used in patients with normal kidney function (eg, revascularization, medical therapy) usually have similar benefits in patients with CKD [<a href="#rid124">124,125</a>]. (See  <a class="medical medical_review" href="/z/d/html/1557.html" rel="external">"Chronic coronary syndrome: Indications for revascularization"</a> and  <a class="medical medical_review" href="/z/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care"</a> and  <a class="medical medical_review" href="/z/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a> and  <a class="medical medical_review" href="/z/d/html/48.html" rel="external">"Overview of the nonacute management of unstable angina and non-ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/46.html" rel="external">"Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization"</a> and  <a class="medical medical_review" href="/z/d/html/47.html" rel="external">"Coronary artery bypass graft surgery in patients with acute ST-elevation myocardial infarction"</a>.)</p><p>Multiple studies have reported that medical therapy commonly used in patients without CKD is employed significantly less frequently in patients with CKD [<a href="#rid13">13,14,126-132</a>]. As an example, a study of 889 patients with an acute coronary syndrome (ACS) evaluated the association between kidney dysfunction, defined as an estimated glomerular filtration rate (GFR) below 60 mL/min per 1.73 m<sup>2</sup>, and in-hospital management and outcomes [<a href="#rid14">14</a>]. Kidney dysfunction was associated with a lower likelihood of receiving percutaneous coronary intervention, and a reduction in the use of a GP IIb/IIIa inhibitor, although the frequency of coronary artery bypass grafting was similar in those with and without kidney dysfunction. Less frequent utilization of angiography, revascularization, and standard medical therapy (eg, angiotensin-converting enzyme inhibitors, beta blockers) in CKD patients after ACS has also been observed in other studies [<a href="#rid126">126,131,132</a>].</p><p>However, not all of the usual treatments used in patients with normal kidney function should be universally applied in patients with CKD. As an example, a meta-analysis of 9969 CKD patients who were having an ACS or percutaneous coronary intervention found that the use of glycoprotein IIb/IIIa inhibitors or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> increased major bleeding episodes without preventing cardiovascular events or death [<a href="#rid122">122</a>]. In addition, automated implantable defibrillators may not provide a survival advantage in patients with CKD [<a href="#rid133">133-135</a>].</p><p class="headingAnchor" id="H18"><span class="h1">PROGNOSIS OF CORONARY HEART DISEASE IN PATIENTS WITH CKD</span><span class="headingEndMark"> — </span>A pervasive finding among patients who suffer coronary events or who have coronary interventions is that those with impaired kidney function have a worse prognosis. The mechanisms which underlie the poor prognosis in patients with CKD are not entirely clear.</p><p>One possibility is that patients who have a coronary event and abnormal kidney function are more likely to have other predictors of adverse outcomes such as older age, hypotension, and lower body weight; these factors may confound the associations observed in the various studies despite statistical adjustment. A second potential explanation is that the adverse outcome (eg, death, recurrent vascular event) ascribed to worse kidney function may instead reflect a more severe acute coronary syndrome (ACS). Because only baseline creatinine values (at the time of presentation with an ACS) were used in most studies to define the presence of CKD, patients with hemodynamic compromise would have been more likely to be defined as having CKD. The formulas used to estimate glomerular filtration rate (GFR) based upon serum creatinine are predicated on there being a <strong>stable</strong> creatinine concentration. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p class="headingAnchor" id="H348910377"><span class="h2">Prognosis after acute coronary syndrome</span><span class="headingEndMark"> — </span>An adverse association between mild to moderate kidney dysfunction and cardiovascular prognosis in patients with ACS has been reported, both in patients with ST elevation myocardial infarction and non-ST elevation ACS. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/77.html" rel="external">"Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes", section on 'Chronic kidney disease'</a> and  <a class="medical medical_review" href="/z/d/html/88759.html" rel="external">"Risk factors for adverse outcomes after ST-elevation myocardial infarction", section on 'Chronic kidney disease'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Prognosis after CABG</span><span class="headingEndMark"> — </span>Although there are some reports of equivalent outcomes [<a href="#rid136">136</a>], most studies demonstrate that decreased kidney function at the time of coronary artery bypass grafting (CABG) is associated with higher risk of adverse outcomes [<a href="#rid127">127,137</a>]. As a consequence, kidney function is included in a commonly used risk prediction algorithm for cardiac surgical mortality  (<a class="graphic graphic_table graphicRef82521" href="/z/d/graphic/82521.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1561.html" rel="external">"Operative mortality after coronary artery bypass graft surgery", section on 'Chronic kidney disease'</a>.)</p><p>In-hospital complication rates and in-hospital as well as long-term mortality are highest among patients on dialysis [<a href="#rid138">138-141</a>].</p><p>Patients with CKD who develop acute kidney injury after CABG may require temporary or permanent dialysis. This issue is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery", section on 'Acute kidney injury'</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Prognosis after PCI</span><span class="headingEndMark"> — </span>The presence of even mild CKD appears to predict an adverse prognosis after percutaneous coronary intervention (PCI) with or without stenting [<a href="#rid15">15,16,142-145</a>], and kidney function is incorporated into a commonly used risk score that predicts one-year mortality following PCI in patients with acute myocardial infarction  (<a class="graphic graphic_table graphicRef70537" href="/z/d/graphic/70537.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/72.html" rel="external">"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome", section on 'Other risk factors'</a> and  <a class="medical medical_review" href="/z/d/html/1587.html" rel="external">"Intracoronary stent restenosis", section on 'Clinical factors'</a>.)</p><p>The observation that revascularization for restenosis is required less frequently when stents are deployed has been made in patients with CKD as it has in patients with normal kidney function [<a href="#rid146">146</a>]. In addition, CKD does not appear to mitigate the angiographic benefits observed with drug-eluting stents [<a href="#rid147">147,148</a>]. (See  <a class="medical medical_review" href="/z/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview"</a>.)</p><p>A separate issue is whether the presence of CKD is associated with higher rates of restenosis. While some studies have found an increased risk of restenosis in patients with CKD [<a href="#rid145">145,149</a>], other studies have reported that CKD is not associated with increased restenosis [<a href="#rid142">142,147</a>].</p><p class="headingAnchor" id="H786391182"><span class="h2">PCI versus CABG in patients with CKD</span><span class="headingEndMark"> — </span>No trials have compared outcomes with PCI versus CABG specifically in patients with moderate to severe CKD. The relative efficacies of PCI with stenting and CABG in patients with mild CKD was addressed in a subgroup analysis from the ARTS trial, which compared multivessel PCI with bare metal stenting to CABG in patients with stable angina. Among the 1205 patients, 290 had CKD as defined by an estimated creatinine clearance ≤60 mL/min (mean 50 mL/min) [<a href="#rid143">143</a>]. A more complete description of this study is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention"</a>.)</p><p>After three years of follow-up, the rate of the primary composite end point of death, myocardial infarction, or stroke was similar with PCI and CABG (adjusted hazard ratio 0.93) but, as in the patients without CKD, CABG was associated with a much lower risk of subsequent revascularization (RR 0.28, 95% CI 0.14-0.54) [<a href="#rid143">143</a>]. This difference persisted at five years, as the rate of a second revascularization procedure remained higher with PCI than CABG (19 versus 8 percent) [<a href="#rid150">150</a>].</p><p>However, the applicability of the findings in ARTS to current practice is uncertain given the widespread use of drug-eluting stents. Uncontrolled observations from ARTS II suggested that outcomes with drug-eluting stents approached those with CABG but data in patients with CKD are not available. (See  <a class="medical medical_review" href="/z/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview"</a> and  <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">INCREASED SERUM CARDIAC ENZYMES AND ACUTE CORONARY EVENTS</span><span class="headingEndMark"> — </span>Cardiac troponins are the preferred marker for the diagnosis of myocardial injury among patients with <strong>normal</strong> kidney function because of their increased specificity compared with CK-MB and other markers. (See  <a class="medical medical_review" href="/z/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>.)</p><p>Cardiac troponins are also used in the diagnosis of myocardial infarction in patients with CKD and a suspected acute coronary syndrome, although minor chronic elevations in serum troponins are commonly observed in patients with CKD who do not have clinical evidence of a myocardial infarction. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1920.html" rel="external">"Cardiac troponins in patients with kidney disease"</a>.)</p><p class="headingAnchor" id="H2090733810"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H1172085258"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Both decreased glomerular filtration rate (GFR) and increased proteinuria increase the risk of cardiovascular disease. These associations have been shown in both community-based populations (ie, cohorts that were not selected specifically to enroll individuals with chronic kidney disease [CKD] or cardiovascular disease) and in populations of patients at high cardiovascular risk (ie, cohorts in which patients with preexisting cardiovascular disease or cardiovascular disease risk factors were specifically recruited). (See <a class="local">'Chronic kidney disease as an independent risk factor for CHD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with CKD often have numerous traditional and nontraditional risk factors for the development of cardiovascular disease. Traditional risk factors (hypertension, smoking, diabetes, dyslipidemia, and older age) appear to be more important risk factors during the earlier stages of CKD. Nontraditional risk factors include uremic toxins, anemia, elevated levels of certain cytokines, an increased calcium load, abnormalities in bone mineral metabolism, and/or an increased inflammatory-poor nutrition state. (See <a class="local">'Presence of traditional and nontraditional cardiovascular risk factors in CKD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among those with CKD, the risk of death, particularly due to cardiovascular disease, is typically higher than the risk of eventually requiring kidney replacement therapy. However, this risk varies with age and other factors. In many studies, older patients with less severe CKD and lower levels of proteinuria are more likely to die (usually due to cardiovascular disease) before needing kidney replacement therapy, while younger patients with proteinuria and diseases localized to the kidney are more likely to ultimately need kidney replacement therapy. (See <a class="local">'Competing risks of cardiovascular and end-stage kidney disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our general approach to reduce the risk of atherosclerotic cardiovascular disease in most patients with CKD not requiring dialysis includes the following (see <a class="local">'Reduction of CHD risk in patients with CKD'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Statin therapy. (See <a class="local">'Statin therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with proteinuric CKD (defined as proteinuria greater than 500 to 1000 mg/day), we recommend angiotensin blockade as part of the antihypertensive regimen. Goal blood pressure is discussed elsewhere. (See <a class="local">'Blood pressure control'</a> above and  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individualized decisions about antiplatelet therapy. (See <a class="local">'Antiplatelet therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In all patients, smoking cessation, maintenance of an ideal body weight, an active lifestyle, and, in patients with diabetes, glycemic control. (See <a class="local">'Other issues'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with CKD require drug dose adjustments and have a higher risk of drug-related adverse effects. Despite the increased risk of adverse effects, the treatments used for established coronary heart disease (CHD) and acute coronary syndrome that are used in patients with normal kidney function (eg, revascularization) may have similar benefits in patients with CKD. (See <a class="local">'Treatment of coronary heart disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with CKD who suffer an acute coronary syndrome or who have coronary interventions (ie, coronary artery bypass grafting, percutaneous coronary intervention [PCI]) have a worse prognosis than patients with normal kidney function who have similar events or procedures  (<a class="graphic graphic_table graphicRef82521" href="/z/d/graphic/82521.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef70537" href="/z/d/graphic/70537.html" rel="external">table 2</a>). The mechanisms which underlie the poor prognosis in patients with CKD are not entirely clear. (See <a class="local">'Prognosis of coronary heart disease in patients with CKD'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154.</a></li><li><a class="nounderline abstract_t">US Renal Data System. USRDS 2009 Annual Data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2010; 55(Suppl 1):S1.</a></li><li><a class="nounderline abstract_t">Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140:167.</a></li><li><a class="nounderline abstract_t">Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004; 15:538.</a></li><li><a class="nounderline abstract_t">Ix JH, Shlipak MG, Liu HH, et al. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J Am Soc Nephrol 2003; 14:3233.</a></li><li><a class="nounderline abstract_t">Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745.</a></li><li><a class="nounderline abstract_t">Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 2003; 42:677.</a></li><li><a class="nounderline abstract_t">Shlipak MG, Stehman-Breen C, Vittinghoff E, et al. Creatinine levels and cardiovascular events in women with heart disease: do small changes matter? Am J Kidney Dis 2004; 43:37.</a></li><li><a class="nounderline abstract_t">Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137:555.</a></li><li><a class="nounderline abstract_t">Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137:563.</a></li><li><a class="nounderline abstract_t">Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002; 106:974.</a></li><li><a class="nounderline abstract_t">Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003; 42:1535.</a></li><li><a class="nounderline abstract_t">McCullough PA, Nowak RM, Foreback C, et al. Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med 2002; 162:2464.</a></li><li><a class="nounderline abstract_t">Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 41:718.</a></li><li><a class="nounderline abstract_t">Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39:1113.</a></li><li><a class="nounderline abstract_t">Reinecke H, Trey T, Matzkies F, et al. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int 2003; 63:696.</a></li><li><a class="nounderline abstract_t">Sosnov J, Lessard D, Goldberg RJ, et al. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis 2006; 47:378.</a></li><li><a class="nounderline abstract_t">Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007; 116:1465.</a></li><li><a class="nounderline abstract_t">Sarnak MJ, Amann K, Bangalore S, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 74:1823.</a></li><li><a class="nounderline abstract_t">Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16:489.</a></li><li><a class="nounderline abstract_t">Hallan S, Astor B, Romundstad S, et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med 2007; 167:2490.</a></li><li><a class="nounderline abstract_t">Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073.</a></li><li><a class="nounderline abstract_t">Tonelli M, Muntner P, Lloyd A, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med 2011; 154:12.</a></li><li><a class="nounderline abstract_t">Pinkau T, Hilgers KF, Veelken R, Mann JF. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J Am Soc Nephrol 2004; 15:517.</a></li><li><a class="nounderline abstract_t">Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63:1121.</a></li><li><a class="nounderline abstract_t">Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41:47.</a></li><li><a class="nounderline abstract_t">Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296.</a></li><li><a class="nounderline abstract_t">Wong TY, Coresh J, Klein R, et al. Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study. J Am Soc Nephrol 2004; 15:2469.</a></li><li><a class="nounderline abstract_t">Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777.</a></li><li><a class="nounderline abstract_t">Knight EL, Rimm EB, Pai JK, et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004; 15:1897.</a></li><li><a class="nounderline abstract_t">Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:1402.</a></li><li><a class="nounderline abstract_t">Fox CS, Larson MG, Keyes MJ, et al. Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: the Framingham Heart Study. Kidney Int 2004; 66:2017.</a></li><li><a class="nounderline abstract_t">Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15:1307.</a></li><li><a class="nounderline abstract_t">Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17:2034.</a></li><li><a class="nounderline abstract_t">Hallan SI, Dahl K, Oien CM, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 2006; 333:1047.</a></li><li><a class="nounderline abstract_t">Van Biesen W, De Bacquer D, Verbeke F, et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28:478.</a></li><li><a class="nounderline abstract_t">Weiner DE, Tighiouart H, Griffith JL, et al. Kidney disease, Framingham risk scores, and cardiac and mortality outcomes. Am J Med 2007; 120:552.e1.</a></li><li><a class="nounderline abstract_t">McCullough PA, Jurkovitz CT, Pergola PE, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007; 167:1122.</a></li><li><a class="nounderline abstract_t">van Domburg RT, Hoeks SE, Welten GM, et al. Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Nephrol 2008; 19:158.</a></li><li><a class="nounderline abstract_t">Choi AI, Li Y, Deeks SG, et al. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121:651.</a></li><li><a class="nounderline abstract_t">Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69:1264.</a></li><li><a class="nounderline abstract_t">Tonelli M, Jose P, Curhan G, et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332:1426.</a></li><li><a class="nounderline abstract_t">Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352:2049.</a></li><li><a class="nounderline abstract_t">Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142:497.</a></li><li><a class="nounderline abstract_t">Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005; 16:3728.</a></li><li><a class="nounderline abstract_t">Seliger SL, Longstreth WT Jr, Katz R, et al. Cystatin C and subclinical brain infarction. J Am Soc Nephrol 2005; 16:3721.</a></li><li><a class="nounderline abstract_t">Bibbins-Domingo K, Chertow GM, Fried LF, et al. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med 2006; 166:1396.</a></li><li><a class="nounderline abstract_t">Menon V, Shlipak MG, Wang X, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147:19.</a></li><li><a class="nounderline abstract_t">Astor BC, Levey AS, Stevens LA, et al. Method of glomerular filtration rate estimation affects prediction of mortality risk. J Am Soc Nephrol 2009; 20:2214.</a></li><li><a class="nounderline abstract_t">Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22:147.</a></li><li><a class="nounderline abstract_t">Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303:423.</a></li><li><a class="nounderline abstract_t">Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380:1662.</a></li><li><a class="nounderline abstract_t">Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380:1649.</a></li><li><a class="nounderline abstract_t">Gutiérrez OM, Khodneva YA, Muntner P, et al. Association between urinary albumin excretion and coronary heart disease in black vs white adults. JAMA 2013; 310:706.</a></li><li><a class="nounderline abstract_t">Thomas B, Matsushita K, Abate KH, et al. Global Cardiovascular and Renal Outcomes of Reduced GFR. J Am Soc Nephrol 2017; 28:2167.</a></li><li><a class="nounderline abstract_t">Leoncini G, Viazzi F, Pontremoli R. Overall health assessment: a renal perspective. Lancet 2010; 375:2053.</a></li><li><a class="nounderline abstract_t">Weiner DE, Tighiouart H, Elsayed EF, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007; 50:217.</a></li><li><a class="nounderline abstract_t">Chang A, Kramer H. Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction. Nephron Clin Pract 2011; 119:c171.</a></li><li><a class="nounderline abstract_t">Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3:514.</a></li><li><a class="nounderline abstract_t">Drawz PE, Baraniuk S, Davis BR, et al. Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. Am Heart J 2012; 164:925.</a></li><li><a class="nounderline abstract_t">Nishimura K, Okamura T, Watanabe M, et al. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study. J Atheroscler Thromb 2014; 21:784.</a></li><li><a class="nounderline abstract_t">Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56:2214.</a></li><li><a class="nounderline abstract_t">Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61:1486.</a></li><li><a class="nounderline abstract_t">van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79:1341.</a></li><li><a class="nounderline abstract_t">Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134:629.</a></li><li><a class="nounderline abstract_t">Segura J, Campo C, Gil P, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15:1616.</a></li><li><a class="nounderline abstract_t">Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12:218.</a></li><li><a class="nounderline abstract_t">Beddhu S, Allen-Brady K, Cheung AK, et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int 2002; 62:1776.</a></li><li><a class="nounderline abstract_t">Knobler H, Zornitzki T, Vered S, et al. Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria. J Am Coll Cardiol 2004; 44:2142.</a></li><li><a class="nounderline abstract_t">Kong AP, So WY, Szeto CC, et al. Assessment of glomerular filtration rate in addition to albuminuria is important in managing type II diabetes. Kidney Int 2006; 69:383.</a></li><li><a class="nounderline abstract_t">Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144:172.</a></li><li><a class="nounderline abstract_t">Perkovic V, Ninomiya T, Arima H, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18:2766.</a></li><li><a class="nounderline abstract_t">Schneider CA, Ferrannini E, Defronzo R, et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008; 19:182.</a></li><li><a class="nounderline abstract_t">Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44:198.</a></li><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.</a></li><li><a class="nounderline abstract_t">Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.</a></li><li><a class="nounderline abstract_t">Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32:853.</a></li><li><a class="nounderline abstract_t">Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137.</a></li><li><a class="nounderline abstract_t">Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012; 380:807.</a></li><li><a class="nounderline abstract_t">Rashidi A, Sehgal AR, Rahman M, O'Connor AS. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol 2008; 102:1668.</a></li><li><a class="nounderline abstract_t">Wattanakit K, Coresh J, Muntner P, et al. Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol 2006; 48:1183.</a></li><li><a class="nounderline abstract_t">Matsushita K, Selvin E, Bash LD, et al. Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 2009; 20:2617.</a></li><li><a class="nounderline abstract_t">Shlipak MG, Katz R, Kestenbaum B, et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 2009; 20:2625.</a></li><li><a class="nounderline abstract_t">Schmieder RE, Mann JF, Schumacher H, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22:1353.</a></li><li><a class="nounderline abstract_t">Tonelli M. Should CKD be a coronary heart disease risk equivalent? Am J Kidney Dis 2007; 49:8.</a></li><li><a class="nounderline abstract_t">Hyre AD, Fox CS, Astor BC, et al. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 2007; 49:37.</a></li><li><a class="nounderline abstract_t">Verhave JC, Gansevoort RT, Hillege HL, et al. Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. J Am Soc Nephrol 2004; 15:1316.</a></li><li><a class="nounderline abstract_t">Verhave JC, Hillege HL, Burgerhof JG, et al. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005; 67:1967.</a></li><li><a class="nounderline abstract_t">Astor BC, Shafi T, Hoogeveen RC, et al. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis 2012; 59:653.</a></li><li><a class="nounderline abstract_t">Shlipak MG, Matsushita K, Ärnlöv J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013; 369:932.</a></li><li><a class="nounderline abstract_t">Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293:1737.</a></li><li><a class="nounderline abstract_t">Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16:529.</a></li><li><a class="nounderline abstract_t">Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005; 80:1270.</a></li><li><a class="nounderline abstract_t">Kobayashi S, Maesato K, Moriya H, et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005; 45:275.</a></li><li><a class="nounderline abstract_t">Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16:1091.</a></li><li><a class="nounderline abstract_t">Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15:218.</a></li><li><a class="nounderline abstract_t">Nakamura S, Ishibashi-Ueda H, Niizuma S, et al. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol 2009; 4:1892.</a></li><li><a class="nounderline abstract_t">Nakano T, Ninomiya T, Sumiyoshi S, et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis 2010; 55:21.</a></li><li><a class="nounderline abstract_t">Russo D, Palmiero G, De Blasio AP, et al. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44:1024.</a></li><li><a class="nounderline abstract_t">Tomiyama C, Higa A, Dalboni MA, et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 2006; 21:2464.</a></li><li><a class="nounderline abstract_t">Dellegrottaglie S, Saran R, Gillespie B, et al. Prevalence and predictors of cardiovascular calcium in chronic kidney disease (from the Prospective Longitudinal RRI-CKD Study). Am J Cardiol 2006; 98:571.</a></li><li><a class="nounderline abstract_t">Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68:766.</a></li><li><a class="nounderline abstract_t">Young JM, Terrin N, Wang X, et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1115.</a></li><li><a class="nounderline abstract_t">Friedman AN, Hunsicker LG, Selhub J, et al. C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int 2005; 68:773.</a></li><li><a class="nounderline abstract_t">Ducloux D, Motte G, Challier B, et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11:134.</a></li><li><a class="nounderline abstract_t">Menon V, Sarnak MJ, Greene T, et al. Relationship between homocysteine and mortality in chronic kidney disease. Circulation 2006; 113:1572.</a></li><li><a class="nounderline abstract_t">Shishehbor MH, Oliveira LP, Lauer MS, et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol 2008; 101:1741.</a></li><li><a class="nounderline abstract_t">Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164:659.</a></li><li><a class="nounderline abstract_t">Patel UD, Young EW, Ojo AO, Hayward RA. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis 2005; 46:406.</a></li><li><a class="nounderline abstract_t">Forsblom C, Harjutsalo V, Thorn LM, et al. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2011; 22:537.</a></li><li><a class="nounderline abstract_t">Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011; 22:545.</a></li><li><a class="nounderline abstract_t">De Nicola L, Minutolo R, Chiodini P, et al. The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. Kidney Int 2012; 82:482.</a></li><li><a class="nounderline abstract_t">Menon V, Wang X, Sarnak MJ, et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int 2008; 73:1310.</a></li><li><a class="nounderline abstract_t">Packham DK, Alves TP, Dwyer JP, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 2012; 59:75.</a></li><li><a class="nounderline abstract_t">Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006; 70:2021.</a></li><li><a class="nounderline abstract_t">Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296:1377.</a></li><li><a class="nounderline abstract_t">Konstantinidis I, Nadkarni GN, Yacoub R, et al. Representation of Patients With Kidney Disease in Trials of Cardiovascular Interventions: An Updated Systematic Review. JAMA Intern Med 2016; 176:121.</a></li><li><a class="nounderline abstract_t">LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425.</a></li><li><a class="nounderline abstract_t">Blood Pressure Lowering Treatment Trialists' Collaboration, Ninomiya T, Perkovic V, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013; 347:f5680.</a></li><li><a class="nounderline abstract_t">Solomon SD, Rice MM, A Jablonski K, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006; 114:26.</a></li><li><a class="nounderline abstract_t">Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; :CD008834.</a></li><li><a class="nounderline abstract_t">Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 156:445.</a></li><li><a class="nounderline abstract_t">Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011) 2013; 3:19.</a></li><li><a class="nounderline abstract_t">Washam JB, Herzog CA, Beitelshees AL, et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation 2015; 131:1123.</a></li><li><a class="nounderline abstract_t">Bangalore S, Maron DJ, O'Brien SM, et al. Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med 2020; 382:1608.</a></li><li><a class="nounderline abstract_t">Weisbord SD, Mor MK, Hochheiser H, et al. Utilization and Outcomes of Clinically Indicated Invasive Cardiac Care in Veterans with Acute Coronary Syndrome and Chronic Kidney Disease. J Am Soc Nephrol 2023; 34:694.</a></li><li><a class="nounderline abstract_t">Gibney EM, Casebeer AW, Schooley LM, et al. Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a national Veterans Administration study. Kidney Int 2005; 68:826.</a></li><li><a class="nounderline abstract_t">Newsome BB, Warnock DG, Kiefe CI, et al. Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease. Am J Kidney Dis 2005; 46:595.</a></li><li><a class="nounderline abstract_t">Han JH, Chandra A, Mulgund J, et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med 2006; 119:248.</a></li><li><a class="nounderline abstract_t">Patel UD, Ou FS, Ohman EM, et al. Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes. Am J Kidney Dis 2009; 53:426.</a></li><li><a class="nounderline abstract_t">Charytan D, Mauri L, Agarwal A, et al. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J 2006; 152:558.</a></li><li><a class="nounderline abstract_t">Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010; 121:357.</a></li><li><a class="nounderline abstract_t">Jukema JW, Timal RJ, Rotmans JI, et al. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Circulation 2019; 139:2628.</a></li><li><a class="nounderline abstract_t">Bansal N, Szpiro A, Reynolds K, et al. Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease. JAMA Intern Med 2018; 178:390.</a></li><li><a class="nounderline abstract_t">Pun PH, Al-Khatib SM, Han JY, et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis 2014; 64:32.</a></li><li><a class="nounderline abstract_t">Tabata M, Takanashi S, Fukui T, et al. Off-pump coronary artery bypass grafting in patients with renal dysfunction. Ann Thorac Surg 2004; 78:2044.</a></li><li><a class="nounderline abstract_t">Zakeri R, Freemantle N, Barnett V, et al. Relation between mild renal dysfunction and outcomes after coronary artery bypass grafting. Circulation 2005; 112:I270.</a></li><li><a class="nounderline abstract_t">Anderson RJ, O'brien M, MaWhinney S, et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5. Kidney Int 1999; 55:1057.</a></li><li><a class="nounderline abstract_t">Dacey LJ, Liu JY, Braxton JH, et al. Long-term survival of dialysis patients after coronary bypass grafting. Ann Thorac Surg 2002; 74:458.</a></li><li><a class="nounderline abstract_t">Liu JY, Birkmeyer NJ, Sanders JH, et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 2000; 102:2973.</a></li><li><a class="nounderline abstract_t">Massad MG, Kpodonu J, Lee J, et al. Outcome of coronary artery bypass operations in patients with renal insufficiency with and without renal transplantation. Chest 2005; 128:855.</a></li><li><a class="nounderline abstract_t">Pinkau T, Mann JF, Ndrepepa G, et al. Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. Am J Kidney Dis 2004; 44:627.</a></li><li><a class="nounderline abstract_t">Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J 2005; 149:512.</a></li><li><a class="nounderline abstract_t">Lemos PA, Arampatzis CA, Hoye A, et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol 2005; 95:167.</a></li><li><a class="nounderline abstract_t">Attallah N, Yassine L, Fisher K, Yee J. Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol 2005; 64:412.</a></li><li><a class="nounderline abstract_t">Stigant C, Izadnegahdar M, Levin A, et al. Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era. Am J Kidney Dis 2005; 45:1002.</a></li><li><a class="nounderline abstract_t">Halkin A, Mehran R, Casey CW, et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. Am Heart J 2005; 150:1163.</a></li><li><a class="nounderline abstract_t">Charytan DM, Varma MR, Silbaugh TS, et al. Long-term clinical outcomes following drug-eluting or bare-metal stent placement in patients with severely reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. Am J Kidney Dis 2011; 57:202.</a></li><li><a class="nounderline abstract_t">Charytan D, Forman JP, Cutlip DE. Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease. Nephrol Dial Transplant 2007; 22:2578.</a></li><li><a class="nounderline abstract_t">Aoki J, Ong AT, Hoye A, et al. Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. Eur Heart J 2005; 26:1488.</a></li></ol></div><div id="topicVersionRevision">Topic 7190 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14581387" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : USRDS 2009 Annual Data report: Atlas of end-stage renal disease in the United States</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14757614" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The metabolic syndrome and chronic kidney disease in U.S. adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978155" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638921" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856780" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520617" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A population-based study of the incidence and outcomes of diagnosed chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14712425" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Creatinine levels and cardiovascular events in women with heart disease: do small changes matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353942" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353943" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acute myocardial infarction and renal dysfunction: a high-risk combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12186803" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14607434" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12437406" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Emergency evaluation of chest pain in patients with advanced kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628712" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11923033" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631136" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490615" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785621" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31582143" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15590763" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071172" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20483451" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21200034" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978153" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631096" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Level of kidney function as a risk factor for cardiovascular outcomes in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12570944" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385656" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339997" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12356629" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213279" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Kidney dysfunction, inflammation, and coronary events: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12234312" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496174" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15100371" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16738019" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Chronic kidney disease and mortality risk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062598" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223665" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17524759" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Kidney disease, Framingham risk scores, and cardiac and mortality outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563019" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178803" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Renal insufficiency and mortality in patients with known or suspected coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100969" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16501489" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714328" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15901858" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cystatin C and the risk of death and cardiovascular events among elderly persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809461" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cystatin C concentration as a risk factor for heart failure in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16251239" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Kidney function as a predictor of noncardiovascular mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236809" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cystatin C and subclinical brain infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832005" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606957" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cystatin C as a risk factor for outcomes in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762497" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Method of glomerular filtration rate estimation affects prediction of mortality risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21164029" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cystatin C identifies chronic kidney disease patients at higher risk for complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124537" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Relation between kidney function, proteinuria, and adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23013602" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23013600" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989654" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Association between urinary albumin excretion and coronary heart disease in black vs white adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28408440" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Global Cardiovascular and Renal Outcomes of Reduced GFR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20483450" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Overall health assessment: a renal perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17631213" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The Framingham predictive instrument in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21811078" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26028594" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23194494" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cardiovascular risk assessment: addition of CKD and race to the Framingham equation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24671110" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594797" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11918756" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307840" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11304102" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15153573" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158211" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12371979" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Impact of renal failure on the risk of myocardial infarction and death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15582311" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16408130" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Assessment of glomerular filtration rate in addition to albuminuria is important in managing type II diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461961" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17804673" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057215" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15264177" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Kidney disease as a risk factor for recurrent cardiovascular disease and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289388" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820460" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859163" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22717317" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064021" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16979003" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892932" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Change in estimated GFR associates with coronary heart disease and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892934" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Rapid decline of kidney function increases cardiovascular risk in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719791" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Changes in albuminuria predict mortality and morbidity in patients with vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185141" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Should CKD be a coronary heart disease risk equivalent?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185144" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15100372" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840045" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The association between atherosclerotic risk factors and renal function in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22305758" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24004120" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cystatin C versus creatinine in determining risk based on kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827312" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625072" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16212138" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15685504" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Insulin resistance in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15743998" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648668" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833908" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Coronary calcification in patients with chronic kidney disease and coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19765871" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558523" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Coronary artery calcification in patients with CRF not undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735378" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923438" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prevalence and predictors of cardiovascular calcium in chronic kidney disease (from the Prospective Longitudinal RRI-CKD Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014054" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389824" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014055" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10616849" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549639" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Relationship between homocysteine and mortality in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18549850" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15037495" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129201" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : CKD progression and mortality among older patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21335512" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21355053" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Risk for ESRD in type 1 diabetes remains high despite renoprotection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22622495" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337713" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Long-term outcomes in nondiabetic chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22051245" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17051142" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16985230" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26619332" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Representation of Patients With Kidney Disease in Trials of Cardiovascular Interventions: An Updated Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755765" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Intensive lipid lowering with atorvastatin in patients with stable coronary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092942" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801465" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23450589" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Antiplatelet agents for chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431677" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018975" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Chapter 1: Definition and classification of CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712269" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32227756" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Management of Coronary Disease in Patients with Advanced Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36735537" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Utilization and Outcomes of Clinically Indicated Invasive Cardiac Care in Veterans with Acute Coronary Syndrome and Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014062" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a national Veterans Administration study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16183413" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490471" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19100672" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923431" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20065168" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882234" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29404570" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24518128" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561032" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Off-pump coronary artery bypass grafting in patients with renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16159830" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Relation between mild renal dysfunction and outcomes after coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027944" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173829" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Long-term survival of dialysis patients after coronary bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113048" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100178" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Outcome of coronary artery bypass operations in patients with renal insufficiency with and without renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15384013" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15864241" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15642546" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16370153" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15957128" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16338253" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21186075" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Long-term clinical outcomes following drug-eluting or bare-metal stent placement in patients with severely reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17517798" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860519" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
